CO2019012271A2 - Péptido activador de receptor de gip - Google Patents
Péptido activador de receptor de gipInfo
- Publication number
- CO2019012271A2 CO2019012271A2 CONC2019/0012271A CO2019012271A CO2019012271A2 CO 2019012271 A2 CO2019012271 A2 CO 2019012271A2 CO 2019012271 A CO2019012271 A CO 2019012271A CO 2019012271 A2 CO2019012271 A2 CO 2019012271A2
- Authority
- CO
- Colombia
- Prior art keywords
- activating peptide
- gip receptor
- receptor activating
- peptide
- peptide compound
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 230000003213 activating effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona un compuesto peptídico novedoso que tiene una acción activadora en los receptores de GIP y el uso del compuesto peptídico como un medicamento. Específicamente, se proporcionan un péptido que contiene una secuencia representada por la fórmula (I) o una sal de este y un medicamento que lo comprende. P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P2 (I) en donde cada símbolo es como se definió en la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017072556 | 2017-03-31 | ||
PCT/JP2018/013540 WO2018181864A1 (en) | 2017-03-31 | 2018-03-30 | Gip receptor activating peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019012271A2 true CO2019012271A2 (es) | 2020-08-21 |
Family
ID=62089992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0012271A CO2019012271A2 (es) | 2017-03-31 | 2019-10-31 | Péptido activador de receptor de gip |
Country Status (21)
Country | Link |
---|---|
US (2) | US10435445B2 (es) |
EP (1) | EP3601329A1 (es) |
JP (2) | JP7175912B2 (es) |
KR (1) | KR20190134626A (es) |
CN (1) | CN110709414A (es) |
AR (1) | AR111346A1 (es) |
AU (2) | AU2018246553B2 (es) |
BR (1) | BR112019020438A2 (es) |
CA (1) | CA3058361A1 (es) |
CL (1) | CL2019002790A1 (es) |
CO (1) | CO2019012271A2 (es) |
EA (1) | EA201992327A1 (es) |
EC (1) | ECSP19078239A (es) |
IL (1) | IL269581B1 (es) |
JO (2) | JOP20180028A1 (es) |
MA (1) | MA48998A (es) |
PE (1) | PE20200675A1 (es) |
PH (1) | PH12019502252A1 (es) |
SG (1) | SG11201908542QA (es) |
TW (1) | TWI801373B (es) |
WO (1) | WO2018181864A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3856768A2 (en) * | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
WO2020067575A1 (en) * | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
AR119471A1 (es) | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
KR20220145888A (ko) | 2020-03-06 | 2022-10-31 | 사노피 | 선택적 gip 수용체 작용제로서의 펩티드 |
MX2022011816A (es) * | 2020-03-25 | 2022-10-10 | Takeda Pharmaceuticals Co | Dosificacion qd de compuestos peptidicos agonistas del receptor de gip y sus usos. |
AR121649A1 (es) * | 2020-03-25 | 2022-06-22 | Takeda Pharmaceuticals Co | Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos |
WO2021198229A1 (en) | 2020-03-31 | 2021-10-07 | Antaros Medical Ab | Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes |
EP4185607A1 (en) | 2020-07-22 | 2023-05-31 | Novo Nordisk A/S | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
WO2022247950A1 (zh) * | 2021-05-28 | 2022-12-01 | 广东众生睿创生物科技有限公司 | 多肽的制备及其应用 |
WO2023031455A1 (en) | 2021-09-06 | 2023-03-09 | Sanofi Sa | New peptides as potent and selective gip receptor agonists |
EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
WO2023193727A1 (zh) * | 2022-04-07 | 2023-10-12 | 广东众生睿创生物科技有限公司 | 多肽在制备治疗和/或预防糖尿病及肥胖症及其相关疾病药物中的制药用途 |
EP4299052A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Gip様活性を有するポリペプチド誘導体及びその用途 |
WO1997010224A1 (en) | 1995-09-13 | 1997-03-20 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
US6329336B1 (en) | 1999-05-17 | 2001-12-11 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
WO2002006234A1 (fr) | 2000-07-17 | 2002-01-24 | Takeda Chemical Industries, Ltd. | Derives de sulfonate, procede de production et utilisation de ces derives |
US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
TW200416029A (en) | 2002-11-01 | 2004-09-01 | Takeda Chemical Industries Ltd | Agent for preventing or treating neuropathy |
AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONNECTION WITH CONDENSED RING |
WO2005030740A1 (ja) | 2003-09-30 | 2005-04-07 | Takeda Pharmaceutical Company Limited | チアゾリン誘導体およびその用途 |
US7820673B2 (en) | 2003-12-17 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same, and use |
BRPI0418148A (pt) | 2003-12-25 | 2007-04-17 | Takeda Pharmaceutical | composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto |
WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
JP4875978B2 (ja) | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
CA2597649A1 (en) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
EP2308839B1 (en) | 2005-04-20 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
WO2006121904A1 (en) * | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
JP5084503B2 (ja) | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | シクロプロパンカルボン酸化合物 |
JPWO2007013694A1 (ja) | 2005-07-29 | 2009-02-12 | 武田薬品工業株式会社 | フェノキシアルカン酸化合物 |
TW200740435A (en) | 2005-08-10 | 2007-11-01 | Takeda Pharmaceuticals Co | Therapeutic agent for diabetes |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
US20090286722A1 (en) | 2005-09-08 | 2009-11-19 | Utech Limited | Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function |
CA2622069A1 (en) | 2005-09-08 | 2007-03-15 | Uutech Limited | Treatment of diabetes related obesity |
US20090186817A1 (en) | 2006-03-21 | 2009-07-23 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
RS52307B (en) | 2006-06-27 | 2012-12-31 | Takeda Pharmaceutical Company Limited | CONDENSED CYCLIC UNITS |
AU2007284365A1 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
US8497240B2 (en) * | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
US8492405B2 (en) | 2006-10-18 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity |
KR101444486B1 (ko) | 2006-10-19 | 2014-09-24 | 다케다 야쿠힌 고교 가부시키가이샤 | 인돌 화합물 |
EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
EA200970746A1 (ru) | 2007-02-09 | 2010-02-26 | Такеда Фармасьютикал Компани Лимитед | Конденсированные циклические соединения в качестве частичных агонистов ppar-гамма |
US8318746B2 (en) | 2007-04-27 | 2012-11-27 | Takeda Pharmaceutical Company Limited | Nitrogen-containing five-membered heterocyclic compound |
WO2008156757A1 (en) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
EP2195034A2 (en) | 2007-09-27 | 2010-06-16 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
PL2300035T3 (pl) | 2008-06-17 | 2016-04-29 | Univ Indiana Res & Tech Corp | Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości |
MX2011001028A (es) | 2008-08-07 | 2011-04-26 | Ipsen Pharma Sas | Analogos truncados de polipeptidos de insulinotropicos dependientes de glucosa. |
JP2011530507A (ja) | 2008-08-07 | 2011-12-22 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | グルコース依存性インスリン分泌刺激ポリペプチドアナログ |
EP2318433A4 (en) | 2008-08-07 | 2012-08-08 | Ipsen Pharma Sas | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES (GIP) MODIFIED AT THE N-TERMINAL END |
EP2987805A3 (en) | 2008-08-07 | 2016-04-13 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
KR20110110174A (ko) | 2008-12-19 | 2011-10-06 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭 |
MX2011013625A (es) | 2009-06-16 | 2012-01-20 | Univ Indiana Res & Tech Corp | Compuestos glucagon activo de receptor de gip. |
US20120157379A1 (en) | 2009-07-31 | 2012-06-21 | Sheau Yu Hsu | Gastric Inhibitory Peptide Variants and Their Uses |
RU2012136450A (ru) | 2010-01-27 | 2014-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
MA34885B1 (fr) | 2010-12-22 | 2014-02-01 | Indiana Unversity Res And Technology Corp | Analogues du glucagon presentant una ctivite de recepteur de gip |
AR084558A1 (es) | 2010-12-22 | 2013-05-22 | Marcadia Biotech | Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1) |
WO2012167744A1 (en) | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
WO2013003449A2 (en) | 2011-06-27 | 2013-01-03 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
IN2014MN02304A (es) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
AR091478A1 (es) | 2012-06-21 | 2015-02-04 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben actividad de receptor de gip (peptido insulinotropico dependiente de glucosa) |
RU2015101697A (ru) | 2012-06-21 | 2016-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, обладающие активностью рецептора gip |
ES2688367T3 (es) | 2012-12-21 | 2018-11-02 | Sanofi | Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón |
TWI638831B (zh) * | 2013-05-28 | 2018-10-21 | 日商武田藥品工業股份有限公司 | 胜肽化合物 |
EP3033355A1 (en) | 2013-08-16 | 2016-06-22 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
CA2929459C (en) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
GB2528436A (en) | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
EP3530671A3 (en) | 2014-09-05 | 2019-11-13 | University of Copenhagen | Gip peptide analogues |
BR112017008659A2 (pt) | 2014-10-29 | 2018-01-30 | Zealand Pharma As | ?métodos e compostos de agonista de gip? |
WO2016077220A1 (en) | 2014-11-10 | 2016-05-19 | Mb2 Llc | Gip/glp-1 co-agonist peptides for human administration |
JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
JP6326394B2 (ja) | 2015-10-09 | 2018-05-16 | Kyb株式会社 | ミキサ車の積載量計量装置 |
WO2017075522A2 (en) | 2015-10-28 | 2017-05-04 | Tufts University | Glp-2 polypeptides with improved proteolytic stability, and methods of preparing and using same |
AU2016382394B2 (en) | 2015-12-31 | 2019-07-04 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist |
WO2017204219A1 (ja) | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | ペプチド化合物 |
-
2017
- 2017-03-31 JO JOP/2018/0028A patent/JOP20180028A1/ar unknown
- 2017-06-16 JO JOP/2019/0211A patent/JOP20190211A1/ar unknown
-
2018
- 2018-03-28 AR ARP180100762A patent/AR111346A1/es unknown
- 2018-03-30 BR BR112019020438A patent/BR112019020438A2/pt unknown
- 2018-03-30 AU AU2018246553A patent/AU2018246553B2/en active Active
- 2018-03-30 CN CN201880035168.2A patent/CN110709414A/zh active Pending
- 2018-03-30 WO PCT/JP2018/013540 patent/WO2018181864A1/en active Application Filing
- 2018-03-30 MA MA048998A patent/MA48998A/fr unknown
- 2018-03-30 EP EP18721166.9A patent/EP3601329A1/en active Pending
- 2018-03-30 KR KR1020197028353A patent/KR20190134626A/ko not_active Application Discontinuation
- 2018-03-30 EA EA201992327A patent/EA201992327A1/ru unknown
- 2018-03-30 JP JP2019553587A patent/JP7175912B2/ja active Active
- 2018-03-30 CA CA3058361A patent/CA3058361A1/en active Pending
- 2018-03-30 PE PE2019001962A patent/PE20200675A1/es unknown
- 2018-03-30 IL IL269581A patent/IL269581B1/en unknown
- 2018-03-30 TW TW107111293A patent/TWI801373B/zh active
- 2018-03-30 SG SG11201908542Q patent/SG11201908542QA/en unknown
- 2018-03-30 US US15/941,030 patent/US10435445B2/en active Active
-
2019
- 2019-08-29 US US16/555,085 patent/US11174301B2/en active Active
- 2019-09-30 PH PH12019502252A patent/PH12019502252A1/en unknown
- 2019-09-30 CL CL2019002790A patent/CL2019002790A1/es unknown
- 2019-10-30 EC ECSENADI201978239A patent/ECSP19078239A/es unknown
- 2019-10-31 CO CONC2019/0012271A patent/CO2019012271A2/es unknown
-
2022
- 2022-02-09 AU AU2022200837A patent/AU2022200837A1/en not_active Abandoned
- 2022-11-09 JP JP2022179703A patent/JP2023012547A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20190134626A (ko) | 2019-12-04 |
TWI801373B (zh) | 2023-05-11 |
CN110709414A (zh) | 2020-01-17 |
PH12019502252A1 (en) | 2020-06-29 |
CL2019002790A1 (es) | 2020-05-29 |
PE20200675A1 (es) | 2020-06-11 |
ECSP19078239A (es) | 2019-12-27 |
JP7175912B2 (ja) | 2022-11-21 |
AR111346A1 (es) | 2019-07-03 |
JOP20190211A1 (ar) | 2019-09-15 |
EP3601329A1 (en) | 2020-02-05 |
TW201841936A (zh) | 2018-12-01 |
AU2022200837A1 (en) | 2022-03-03 |
MA48998A (fr) | 2020-02-05 |
IL269581B1 (en) | 2024-02-01 |
CA3058361A1 (en) | 2018-10-04 |
WO2018181864A1 (en) | 2018-10-04 |
US20180298070A1 (en) | 2018-10-18 |
AU2018246553B2 (en) | 2021-11-11 |
AU2018246553A1 (en) | 2019-10-17 |
US20200140505A1 (en) | 2020-05-07 |
BR112019020438A2 (pt) | 2020-06-09 |
EA201992327A1 (ru) | 2020-02-19 |
JP2023012547A (ja) | 2023-01-25 |
IL269581A (en) | 2019-11-28 |
US11174301B2 (en) | 2021-11-16 |
SG11201908542QA (en) | 2019-10-30 |
JP2020515612A (ja) | 2020-05-28 |
JOP20180028A1 (ar) | 2019-01-30 |
US10435445B2 (en) | 2019-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019012271A2 (es) | Péptido activador de receptor de gip | |
ECSP15044389A (es) | Compuesto peptídico | |
CO2020001879A2 (es) | Compuesto heterocíclico y su uso | |
CL2019000415A1 (es) | Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéuticos de una infección por el virus del vih. | |
CR20150454A (es) | Compuestos amida para el tratamiento de vih | |
AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
ECSP17002135A (es) | Compuestos antiproliferativos y métodos de uso de los mismos | |
AR094309A1 (es) | Compuesto heterociclico fusionado y uso del mismo para el control de plagas | |
CR20160241A (es) | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b | |
CL2020000487A1 (es) | Agentes antivirales contra la hepatitis b. | |
ECSP16067137A (es) | Compuesto heterocíclico fusionado | |
ECSP16067163A (es) | Compuesto heterocíclico | |
BR112016025819A2 (pt) | vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico | |
CL2022001529A1 (es) | Nuevos derivados de metilquinazolinona | |
GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
ECSP16096831A (es) | Derivados de naftiridinadiona | |
BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
CO2018003909A2 (es) | Compuestos terapéuticos y sus métodos de uso | |
UY37166A (es) | Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano | |
CR20150533A (es) | Compuesto peptídico | |
AR122557A2 (es) | Oligonucleótido modificado | |
AR111017A1 (es) | Sal hemisulfato de un compuesto nucleotídico para el tratamiento del virus de la hepatitis c | |
UA112287U (xx) | Застосування вінборону для нівелювання антипроліферативного впливу ібупрофену на шлунковий епітелій | |
TH165161A (th) | สารประกอบเพพไทด์ |